Nifty Pharma gains as WuXi curbs lift CDMOs in 2026

What moved pharma stocks on June 9

Pharma shares traded higher on June 9, with several contract development and manufacturing related names rising as investors reacted to developments involving Chinese contractor WuXi AppTec Co. The Pentagon named WuXi AppTec on a list of firms associated with the Chinese military. The move matters for global drugmakers because WuXi is a major pharmaceutical contractor, and any restrictions or heightened scrutiny can complicate research and outsourcing decisions for American drug companies.

In the Indian market, the immediate read-through was supportive for domestic CRDMO and CDMO players that compete with Chinese outsourcing firms for global projects. Traders and investors focused on the possibility of incremental business shifting toward India as customers look to diversify supply chains.

Nifty Pharma and top gainers: where the index stood

At 11:05 am on June 9, the Nifty Pharma index was trading 1% higher at 24,374.45. Within the index, Divi's Laboratories, Piramal Pharma, Zydus Life, and Laurus Labs led gains, rising 3.3%, 2.1%, 1.95%, and 1.85%, respectively.

The broader theme was that any pressure on a major China-linked contractor could improve the competitive positioning of Indian outsourcing and manufacturing platforms, particularly in complex chemistry and integrated development-to-manufacturing services.

Why WuXi’s Pentagon listing matters for outsourcing

WuXi AppTec’s inclusion on a Pentagon list introduces uncertainty around how American customers will manage vendor risk, compliance processes, and long-term supply plans. Even without immediate operational changes being spelled out in the market update, the headline increases the perceived friction for US-linked projects routed through the named contractor.

For Indian CRDMO and CDMO companies, the market’s reaction reflects a familiar pattern: when global buyers reassess China concentration risk, diversified capacity in India tends to attract attention. The June 9 price action suggested investors were positioning for that shift, even as the actual pace of contract wins typically plays out over multiple quarters.

Indian CDMO and CRDMO players in focus

The move was seen as constructive for Indian CDMO players such as Divi's Labs, Neuland Laboratories, Piramal Pharma, and Sai Life Sciences. These companies operate across different parts of the outsourced value chain, from development support to commercial manufacturing, and can benefit when global pharma looks for alternatives.

The immediate gains were not limited to one name, indicating the market treated it as a sector-wide catalyst rather than a company-specific development.

Jefferies flags Sai Life Sciences as a top CRDMO pick

Separately, Jefferies highlighted Sai Life Sciences Ltd. as its top pick in the contract research, development, and manufacturing organisation (CRDMO) space. The brokerage cited the company’s integrated business model, growth outlook, and pipeline as key drivers.

Jefferies maintained a ‘Buy’ rating and revised its price target to ₹1,300, which it said implies a 29% upside. It also raised estimates, increasing its FY28 sales estimate by 3% and earnings per share estimate by 5%.

Jefferies noted that Sai Life Sciences is a pure-play CRDMO, with no unrelated business divisions. It also pointed to the company’s “follow-the-molecule” model, presence in oligos, global presence, a clean balance sheet, and the absence of a private equity supply overhang as supportive factors, while stating valuations were in line with peers despite robust growth.

Sai Life’s growth metrics and demand shift narrative

Sai Life Sciences is described as the fastest-growing CRDMO among listed Indian peers in terms of revenue CAGR and EBITDA CAGR from FY22 to FY24. Jefferies also said the company delivered 23% sales CAGR and 57% EBITDA CAGR over the past three years.

In the same sector framing, Jefferies said it expects sales and EBITDA to grow at a CAGR of 17% and 20%, respectively, between FY26 and FY28. The brokerage also described Sai Life Sciences as a key beneficiary among India’s CRDMOs, citing “unprecedented demand” from Big Pharma clients to diversify away from China.

Stock levels, debut context, and Jefferies scenarios

Sai Life Sciences listed in December 2024 at a premium of a little more than 18% over its IPO price of ₹650. The stock has gained 56% from its listing price and 85% from its IPO price, based on the figures cited.

Jefferies set a base target price of ₹1,300 per share for Sai Life Sciences, implying an upside potential of more than 28% from the previous closing price of ₹1,014 on the NSE. It also outlined scenario outcomes, with an upside scenario of ₹1,500 (+48%) and a downside scenario of ₹800 (-21%).

Jefferies lifts Divi’s target, keeps CRDMO picks unchanged

Jefferies increased the target price for Divi's Laboratories from ₹7,850 to ₹8,000 while maintaining a ‘Buy’ rating. It also said its top picks within the CRDMO segment remain Sai Life Sciences and Divi’s Laboratories, citing execution strength and growth prospects.

A separate Jefferies note also stated it sees robust long-term prospects for the space but advised short-term selectivity, adding that a softer base should aid growth optics from H2 CY26.

Key data points at a glance

Market impact: what the moves signal for Indian pharma outsourcing

The June 9 rally showed how sensitive Indian pharma outsourcing names are to global policy and compliance headlines tied to China. The immediate sector move was visible both in the Nifty Pharma index level and in individual gains for large and mid-cap names linked to outsourcing and manufacturing.

Alongside the geopolitical headline, broker research added stock-specific fuel. Jefferies’ higher targets for Sai Life Sciences and Divi’s Laboratories provided investors with updated valuation anchors at a time when the market was already focused on potential diversification of global outsourcing.

Analysis: why investors are watching CRDMO execution closely

The positive read-through is not only about near-term sentiment. The details in Jefferies’ note highlight what investors typically track in CRDMO businesses: integrated service models, pipeline depth, win rates, and expansion into newer modalities such as oligos.

At the same time, the “short-term selectivity” comment underscores that even in a supportive multi-year environment, stock performance can diverge based on execution and timing. The market response on June 9, combined with the broker’s emphasis on execution strength, suggests investors are likely to continue differentiating between companies with scale and proven delivery versus those still building capabilities.

Conclusion

Indian pharma and CRDMO-linked stocks moved higher on June 9 as the Pentagon’s WuXi AppTec listing raised fresh questions around China-linked outsourcing exposure, while Jefferies reiterated buy calls on Sai Life Sciences and Divi’s Laboratories with higher targets. Attention is likely to stay on CRDMO demand trends and on subsequent broker and company updates around client diversification, pipeline progress, and growth expectations into FY28 and beyond.